Artificial Intelligence System for Multi-Cancer Detection Support

Informazioni relative al progetto

AI-MICADIS

ID dell’accordo di sovvenzione: 835911

DOI

10.3030/835911

Progetto chiuso

Data della firma CE 21 Dicembre 2018

Data di avvio 1 Gennaio 2019

Data di completamento 30 Giugno 2019

Finanziato da

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Costo totale

€ 71 429,00

Contributo UE

€ 50 000,00

Coordinato da

ARTIFICIAL INTELLIGENCE EXPERT SRL
Romania

Periodic Reporting for period 1 - AI-MICADIS (Artificial Intelligence System for Multi-Cancer Detection Support)

Periodo di rendicontazione: 2019-01-01 al 2019-06-30

Sintesi del contesto e degli obiettivi generali del progetto

The stage of cancer progression at the time of diagnosis is strongly associated with patient survival. The World Health Organization is urging governments to accelerate action to reduce premature mortality from cancer and decrease the number of people that die from cancer each year (currently > 8M). The current diagnostic tests and screening tools have very disappointing accuracy rates and many patients remain undiagnosed.
AIE is developing a ground-breaking solution that will enable early diagnoses and screening for a wide variety of cancers. By using circulating microRNAs, instead of the commonly used circulating tumour DNA or circulating cancer cells, and by using powerful Deep Learning Artificial Intelligence algorithms to analyse Real Time PCR, microarray or NGS data, AIE is developing an extremely accurate diagnostic tool that can be used for detecting the earliest stages of cancer progression.

The main objectives of this study were to obtain insights into the needs of the envisioned targeted users and the commercial viability of the platform as a service and a product. Furthermore, the objective was to use the results of the activities carried out in the feasibility study to define the exploitation and commercialization strategy.

Artificial Intelligence Expert has demonstrated the feasibility of the AI-MICADIS platform both as a service and as a product. The feasibility study determined that the commercialization strategy should follow a staggered approach and the first and second cancer indication were identified based on market research, user interviews, and surveys. The targeted customers’ willingness to buy of both the service and the platform was established.

Lavoro eseguito dall’inizio del progetto fino alla fine del periodo coperto dalla relazione e principali risultati finora ottenuti

To assess the commercial viability of AI-MICADIS, Artificial Intelligence Expert performed an in-depth market analysis to understand its drivers and the main players, researched the needs and demands of researchers and clinicians regarding a miRNA-based diagnostic and screening test though interviews and surveys, and identified the main barriers for commercialization.
Furthermore, the advisory board was extended to include advisors with extensive business acumen, the platform training was further improved and indications to its potential use added, an initial Freedom-to-Operate analysis was performed and an initial regulatory roadmap was drafted.
The study showed that the commercialization of AI-MICADIS is feasible. The barriers that were identified can be overcome with the right mitigation strategies. To maximize implementation of the technology, AIE will focus to commercialize the platform for one indication first, quickly followed up with a second indication. A partnership with a diagnostic test developing company or pharmaceutical company is envisioned to optimize the exploitation and dissemination of the technology. The first potential partners have been contacted and discussion regarding collaborations are currently ongoing.

Progressi oltre lo stato dell’arte e potenziale impatto previsto (incluso l’impatto socioeconomico e le implicazioni sociali più ampie del progetto fino ad ora)

Artificial Intelligence Expert positively assessed the feasibility of AI-MICADIS, a platform technology that has an unprecedented accuracy, and thereby facilitating early cancer diagnosis and screening. This platform technology can significantly contribute to the goal of the World Health Organization to accelerate action to reduce premature mortality from cancer and decrease the number of people that die from cancer.

Artificial Intelligence Expert's AI-MICADIS platform technology